Sulfidopeptide leukotrienes mediate acrolein-induced bronchial hyperresponsiveness

Area of Science:

• Pulmonary Pharmacology
• Respiratory Medicine
• Toxicology

Background:

• Sulfidopeptide leukotrienes are key bronchoconstrictive mediators in asthma pathophysiology.
• Acrolein is an environmental toxin implicated in respiratory distress.

Purpose of the Study:

• To investigate the efficacy of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in mitigating acrolein-induced bronchial hyperresponsiveness.
• To determine if acrolein exposure augments leukotriene (LT) C4 generation.

Main Methods:

• Guinea pigs were exposed to acrolein (1.3 ppm for 2 h) and bronchial responsiveness to acetylcholine was measured.
• Bronchoalveolar lavage fluid was analyzed for leukotriene C4 concentrations.
• Animals were treated with a leukotriene receptor antagonist (L-649,923) or 5-lipoxygenase inhibitors (L-651,392, U-60,257).

Main Results:

• Acrolein exposure significantly increased airway resistance and bronchial hyperresponsiveness, which persisted for 24 hours.
• Leukotriene C4 generation was significantly elevated in bronchoalveolar lavage fluid after acrolein exposure.
• Treatment with L-649,923, L-651,392, and U-60,257 diminished immediate bronchoconstriction and inhibited bronchial hyperresponsiveness.
• L-651,392 treatment inhibited the acrolein-induced increase in leukotriene C4.

Conclusions:

• Acrolein induces significant bronchial hyperresponsiveness and increases leukotriene C4 generation in guinea pigs.
• Leukotriene receptor antagonists and 5-lipoxygenase inhibitors are effective in reducing acrolein-induced airway inflammation and hyperresponsiveness.
• Targeting the leukotriene pathway may be a therapeutic strategy for acrolein-related respiratory conditions.